• Contact ArQule
  • About ArQule
  • Product R & D
  • Clinical Trials
  • Investors and Media
    • Press Releases
    • Events
    • Corporate Presentation
    • Recent Data Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Contact Us
  • Careers
Shareholder Tools
Briefcase Shareholder Briefcase
Email Alerts Email Alerts
Download Center Download Library
snapshot Snapshot
Mobile Investor Mobile Investor
RSS RSS News Feeds
 
Search Investor Relations

Print   Email   Share
Share this on: Close window
delicious delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Mixx Mixx
Twitter Twitter
Yahoo Buzz Yahoo! Buzz
What is this?

Home : Investors and Media

Investors and Media

Our mission as a biotechnology company is to research, develop and commercialize a next-generation of small molecule cancer therapeutics. We are combining innovative, proprietary anti-cancer technology with world-class chemistry capabilities to generate drug candidates that target multiple tumor types, act selectively against cancer cells and are well tolerated by patients. Our lead products are in clinical development, and our research pipeline targets multiple molecules with established roles and therapeutic potential in cancer.

We are headquartered and operate research facilities and development programs in Woburn, Massachusetts.

 

Recent Releases

Mar 4, 2010
ArQule, Inc. to Present at Cowen and Company Health Care Conference

Mar 2, 2010
ArQule Reports Fiscal 2009 Year End and Fourth Quarter Results



Events & Presentations

Mar 2, 2010 at 9:00 AM ET
Q4 2009 ArQule, Inc. Earnings Conference Call

Mar 9, 2010
Corporate Presentation


Stock Chart Stock Quote
Stock price graph
3 Mo.   6 Mo.   1 Yr.
ArQule NASDAQ: ARQL
Price: 3.53
Change: + 0.02
Day High: 3.59
Day Low: 3.49
Volume: 130,400
Delayed at least 20 minutes.
Provided by eSignal.


Transfer Agent
American Stock and Transfer
41 Wall Street
New York City, NY 10005
Phone: 212-936-5100



Public Financings - Facts at a Glance

IPO date: October 16, 1996
IPO offering price: $12.00
IPO total gross proceeds: $34 million
IPO shares sold: 2.88 million
High since IPO: $40.38 (2/17/00)
Low since IPO: $1.92 (3/10/03)
Follow-on offering date: April 4, 1997
Follow-on offering price: $12.00
Follow-on total gross proceeds: $24 million
Follow-on shares sold: 2 million
Follow-on offering date: November 21, 2000
Follow-on offering price: $22.50
Follow-on total gross proceeds: $76 million
Follow-on shares sold: 3,358,000
Follow-on offering date: January 28, 2005
Follow-on offering price: $5.25
Follow-on total gross proceeds: $30 million
Follow-on shares sold: 5,790,000
Follow-on offering date: June 19, 2007
Follow-on offering price: $7.75
Follow-on total gross proceeds: $58 million
Follow-on shares sold: 7,502,000
© ArQule, 2010 | Terms and Conditions: Purchasing | Terms of Use